No association between the rs10503253 polymorphism in the CSMD1 gene and schizophrenia in a Han Chinese population by Yansong Liu et al.
RESEARCH ARTICLE Open Access
No association between the rs10503253
polymorphism in the CSMD1 gene and
schizophrenia in a Han Chinese population
Yansong Liu1, Zaohuo Cheng2, Jun Wang2, Chunhui Jin2, Jianmin Yuan2, Guoqiang Wang2, Fuquan Zhang2*
and Xudong Zhao1*
Abstract
Background: Schizophrenia (SCZ) is a complex, heritable, and devastating psychiatric disorder. Recent genome-wide
association studies have identified a single-nucleotide polymorphism (SNP; rs10503253) in the CUB and SUSHI multiple
domains 1 (CSMD1) gene as a risk factor for SCZ. In this study, we investigated whether the rs10503253 in CSMD1
contributes to the risk of SCZ in a Han Chinese population.
Methods: We conducted a case-control study in a population from eastern China, involving 1378 SCZ patients and
1091 unrelated healthy controls, using the ligase detection reaction–polymerase chain reaction method to genotype
the rs10503253 polymorphism in the CSMD1 gene.
Results: No significant association was found between the SCZ patients and controls for any allele or genotype
frequency of the SNP rs10503253 (all P > 0.05).
Conclusions: Our findings do not support an association between CSMD1 rs10503253 and SCZ in a Han Chinese
population.
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Background
Schizophrenia (SCZ) is a common and heritable psychi-
atric disorder that affects approximately 1 % of the general
population worldwide, characterized by hallucinations, de-
lusions and cognitive deficits, and incompatibility of men-
tal activity and environment. Although genetic factors
account for more than 80 % of the etiology and heritability
of SCZ, the exact etiology and genetic mechanism of the
disease are still unknown [1, 2].
The CUB and Sushi multiple domains-1 (CSMD1)
gene, located on 8p23.2, is a complement control-related
protein, and CSMD1 is highly expressed in the central
nervous system (CNS) [3]. Although the exact functions
of this gene remain unclear, it has been reported that
CSMD1 may play an important role in modulating the
ratio between dopamine and serotonin metabolites in
CNS [4]. Recently, a single-nucleotide polymorphism
(SNP) of CSMD1, rs10503253, has been identified by a
large-scale genome-wide association study (GWAS) in
samples of European ancestry as a risk genetic variant
for SCZ [5]. Subsequent studies have replicated the asso-
ciation of rs10503253 with SCZ in subjects of European
ancestry [6, 7]. This association was recently confirmed
in an enlarged GWAS [8] by the group [5].
The CSMD1 gene has been validated as a target of
miR-137 [9], which is involved in regulation adult neuro-
genesis [10] and neuron maturation [11], and is related
to the pathogenesis of SCZ. In addition, several studies
have revealed that the A allele of rs10503253 is associ-
ated with cognitive dysfunction, which has been docu-
mented as a primary and core deficit of SCZ [7, 12].
Therefore, CSMD1 is considered to be an important sus-
ceptibility gene for SCZ.
Although several studies supported the association of
CSMD1 rs10503253 with SCZ, Ohi et al. [13] failed to
replicate this result in samples from Japanese descent.
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Given that different ethnic populations may exhibit gen-
etic heterogeneity of SCZ and only several genes have
been consistently associated with SCZ across multiple
studies in different genetic populations, it is necessary to
investigate the possible relationship between this genetic
locus and SCZ among other independent populations.
To further evaluate the association of CSMD1
rs10503253 with SCZ, we conducted a case-control




The study sample included 1378 patients with SCZ (854
males and 524 females; mean age = 45.92 years at re-
cruitment, standard deviation (SD) = 11.51) and 1091
matched unrelated healthy controls (607 males and 484
females; mean age = 45.01 years at recruitment, SD =
10.31), drawn from a population of people of Han
descent (Table 1).
For the patient group, the diagnosis of SCZ was con-
firmed by at least two experienced psychiatrists accord-
ing to the Structured Clinical Interview for DSM-IV
(SCID-I) and the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV) criteria for SCZ. Exclusion
criteria included the presence of other mental disorders,
neurodevelopmental disorders or significant organic
brain injury, epilepsy, and alcohol addiction or substance
abuse. For the selection of control subjects, the Struc-
tured Clinical Interview for DSM-IV and Non-patients
edition (SCID-NP) were used to interview members of
an unrelated healthy general population, and those who
met any psychiatric diagnosis within the SCID-I Axis I
were excluded. Subjects with any family history of psy-
chiatric disease among first-degree relatives were also
excluded. The control subjects lived in the same geo-
graphical area as the patients, and were group matched
to the patients by age, gender, and ethnicity. Any subject
not born in Jiangsu was excluded, based on a self-
reported questionnaire regarding the ancestral and ori-
gin birth places.
The clinical research was in compliance with the
World Medical Association Declaration of Helsin-
ki—Ethical Principles for Medical Research Involving
Human Subjects. This study was approved by the Ethics
Committees of the Wuxi Health Mental Center, and
signed informed consent was obtained from all partici-
pants, or from his/her guardians when the participant
had no capacity to consent. Healthy subjects were re-
cruited by advertisement. Before being enrolled in the
present study, each subject was also required to sign a
consent form.
DNA extraction and SNP genotyping
Peripheral blood samples were collected from all sub-
jects using K2EDTA tubes. Genomic DNA was extracted
from 150 μl of peripheral blood using a blood genotyp-
ing DNA extraction kit (Tiangen Biotech, Beijing,
China). DNA samples were then stored at −80 °C for
genotype analysis.
SNP genotyping was performed using the ligase detec-
tion reaction–polymerase chain reaction (LDR-PCR)
method [14, 15] by the Shanghai Biowing Applied Bio-
technology Co., Ltd. (www.biowing.com.cn). Genomic
DNA extracted from the clinical samples was first sub-
jected to multiplex PCR to obtain a PCR product includ-
ing SNPs. The PCR primers for SNP rs10503253 were
5’-CATAAGTTTATATTTCTCAC-3’ (forward) and 5’-
CTGTAGCAGGTTCAACAGAC-3’ (reverse). This PCR
product and the LDR probes were then subjected to a
multiplex LDR reaction, with a DNA sequencer used to
detect the products.
Statistical analysis
All statistical analyses were performed using the online
software platform SHEsis (http://analysis.bio-x.cn/myA-
nalysis.php) [16], including association studies, Hardy–
Weinberg equilibrium (HWE) tests, and the calculation
of genotype and allele frequencies between patients with
SCZ and healthy controls. The power analysis for our
sample size was performed using the G*power analysis
program [17] based on Cohen’s method [18]. P values of
less than 0.05 were considered statistically significant.
Results
Data from 1378 patients with SCZ and 1091 unrelated
healthy controls were analyzed. HWE tests indicated
Table 1 Demographic characteristics of the study subjects
Group Case (n, %) Control (n, %)
Sex
Total 1378 1091
M 854 (62) 607 (56)
F 524 (38) 484 (44)
Age
Range 14–76 16–77
Mean 45.92 ± 11.51 45.01 ± 10.31
14–19 10 (1) 4 (0)
20–29 141 (10) 97 (9)
30–39 201 (15) 174 (16)
40–49 489 (35) 455 (42)
50–59 375 (27) 275 (25)
60–69 151 (11) 80 (7)
70–76 11 (1) 6 (1)
M Male, F Female
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that the genotype frequency distribution of rs10503253
did not significantly deviate from HWE (P = 0.15 for
cases; P = 0.35 for controls). The total genotyping rate in
all individuals was 99.51 %. In addition, we calculated
the power of this study using the G*power program de-
scribed by Li et al [19]. The results showed that our
sample size revealed 99.87 % power to detect a signifi-
cant association (α < 0.05) when an effect size index of
0.1 (corresponding to a weak gene effect) was used.
When an effect size index of 0.2, which corresponds to a
weak to moderate gene effect was used, the sample size
showed 100 % power in detecting a significant (a < 0.05)
allele and genotype association.
The results of our association study suggested that the
A allele of SNP rs10503253 within CSMD1 was not sig-
nificantly associated with SCZ risk (P = 0.26, OR = 1.07,
95 % CI: 0.95–1.21) in a Han Chinese population sample
(see Table 2). Furthermore, stratification analysis by gen-
der did not show any positive association between SCZ
and the A allele of SNP rs10503253. A detailed summary
is shown in Table 3. The statistical results suggest that
the A allele of SNP rs10503253 in CSMD1 might not be
a risk locus for SCZ susceptibility in Han Chinese
populations.
Discussion
Previous studies have indicated that the activity of com-
plement components (including complement component
C3) is tightly controlled in the brain [20], and deregula-
tion of complement has been found to be involved in
psychiatric disorders such as SCZ [21, 22]. CSMD1 is a
complement control-related protein and plays a role in
inhibition of complement C3 activation [23, 24]. In
addition, it has been reported that CSMD1 is under the
control of miR-137 [9], which is implicated in the regu-
lation of adult neurogenesis [10] and neuron maturation
[11], and is therefore related to the pathogenesis of SCZ.
Furthermore, the CSMD1 gene has been reported to be
associated with cognitive dysfunction, which has been
recognized as a primary deficit in SCZ [7, 12]. These re-
sults suggest that the CSMD1 gene could be an import-
ant factor for SCZ.
Recent GWASs have identified the A allele of SNP
rs10503253 as a risk allele for SCZ [5–8]. However, Ohi
et al. [13] failed to replicate the association between
rs10503253 and SCZ. In our dataset, we also did not de-
tect the association of rs10503253 with SCZ in a Han
Chinese population. This inconsistency might result
from the different genetic backgrounds. In the current
study, the Han Chinese samples were all recruited from
the Jiangsu province of China, the participants in the
study by Ohi et al. [13] were people of Japanese descent,
while the study samples in the studies by Ripke et al. [5]
and Cross-Disorder Group of the Psychiatric Genom-
ics Consortium [6] were all individuals of European
ancestry. Furthermore, the samples in the study by
Ripke et al. [8] were cohorts of admixed ethnicities
from European and East Asian ancestry. The A allele
frequencies of the rs10503253 SNP of CSMD1 in
healthy controls from our study and the studies by
Ohi et al. [13], Ripke et al. [5], Cross-Disorder Group
of the Psychiatric Genomics Consortium [6] and
Ripke et al. [8] were 0.30, 0.32, 0.19, 0.20 and 0.22,
respectively. The differences in the CSMD1 poly-
morphism profiles suggest that populations from dif-
ferent ethnicities might exhibit genetic heterogeneity
of SCZ. Additionally, sampling errors caused by dif-
ferences in clinical diagnosis of SCZ might also con-
tribute to the inconsistency.
There are some limitations to the interpretation of
our results. First, in this study we only investigated
the SNP rs10503252 in the CSMD1 gene. Other SNPs
across the CSMD1 gene may be linked with SCZ and
cause alterations in Han Chinese populations. Second,
the Han Chinese participants in this study were all
recruited from Jiangsu Province, and Han Chinese
populations from different geographical areas might
also exhibit genetic heterogeneity of SCZ. It is there-
fore unlikely that our findings can be extended to all
people of Han descent. Third, the sample size of our
study is still relatively small compared with current
large-scale genetic studies [5, 6, 8], and the associ-
ation of CSMD1 with SCZ needs to be tested in more
samples.
Conclusions
In summary, this case-control study in a Han Chinese
population did not support the association of CSMD1
rs10503252 with SCZ risk, as reported in earlier GWASs
studies. We hope that this finding contributes to a better
Table 2 Frequencies of alleles and genotypes for rs10503253 in SCZ patients and controls
Group n Allele P OR (95 % CI) genotype P HWE
A (n, %) C (n, %) A/A (n, %) A/C (n, %) C/C (n, %)
Case 1378 861 (31) 1895 (69) 0.26 1.07 (0.95–1.21) 123 (9) 615 (45) 640 (46) 0.50 0.15
Control 1091 649 (30) 1533 (70) 90 (8) 469 (43) 532 (49) 0.35
OR Odds Ratio, 95 % CI 95 % Confidence Interval, HWE Hardy–Weinberg equilibrium
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understanding of the relationship between CSMD1 gen-
etic variants and SCZ pathogenesis. However, other
SNPs within CSMD1 are still possible risk SNPs for SCZ
susceptibility, and further research could focus on find-
ing other potential risk variants within CSMD1 for SCZ.
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